Integra LifeSciences shares jumped 4.3% after BMO Capital initiated coverage with a Market Perform rating and a $19 price target. The firm cited the return of Essig as CEO for operational continuity and noted early recovery signs including a first-quarter 2026 earnings beat and record Integra Skin production. The initiation followed an upgrade from Argus to Buy with a $25 price target. Shares traded at $18.09, up 4.5% from the previous close.
Integra LifeSciences HoldingsBMO Capital initiated coverage with Market Perform rating and $19 price target, and Argus upgraded to Buy with $25 target.